C
Carl D Regillo
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Nov 9, 2026
Retina Society 2026: What Could Affect Practice Right Now?
Y
1:40Yashin ModiGUEST
What did these findings add to our understanding of treatment durability and disease control in everyday practice?
C
1:47Carl RegilloGUEST
Well, we are learning a lot from real-world studies, and these are mostly large databases that are indicating mostly about how durable these drugs are, that is, furosemab and high-dose aflibrocept.
C
2:00Carl RegilloGUEST
And it's all pointing in the same direction, and I'm going to ask you if you think that's what it's like in your experience as a practitioner, but it is...
C
2:09Carl RegilloGUEST
Basically, what I'm seeing, which I'm seeing definitively more durability with these, we'll call them, quote, second-generation drugs.
C
2:18Carl RegilloGUEST
But the data in particular presented at Retina Society pointed to mean or median durability in the maintenance phase, especially for wet AMD and also for DME to some degree, too, right in that 11, 12 weeks.
C
2:31Carl RegilloGUEST
When you compare that to what's been published in the past with the first generation drugs, standard dose, aflipracept, ranibizumab, they're more in the eight to nine weeks.
7 MINS LATER
Y
9:12Yashin ModiGUEST
What are your thoughts on the data that was presented at Retina Society, and how does that bear out in your own experience?
AAO '26: BRUNELLO and LUGANO
19:54
C
16:29Carl RegilloGUEST
Before we get to that, one more point about what EYP-1901 is, because it's more than just virolinib.
C
16:35Carl RegilloGUEST
It's virolinib as a small molecule packaged in a bioerodible polymer that's injected intravitrally.
C
16:42Carl RegilloGUEST
So this insert stays in the vitreous cavity and delivers therapeutic levels of the virolinib intravitrally for at least six months.
C
16:57Carl RegilloGUEST
Now on to the clinical trials, because the clinical trial program in general for 1901 is large and robust, looking at both neovascular AMD and diabetic macrogema, both of which have been phased through testing successfully.

Greg NotesteinHOST
Can you talk us through that asymmetric cohort, help us define it and understand who was in that cohort?